Detalhe da pesquisa
1.
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
N Engl J Med
; 389(4): 297-308, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356066
2.
The Importance of Early Diagnosis and Intervention in Chronic Kidney Disease: Calls-to-Action from Nephrologists Based Mainly in Central/Eastern Europe.
Kidney Blood Press Res
; 49(1): 218-227, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38442701
3.
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Ann Intern Med
; 176(1): 59-66, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469914
4.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510542
5.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Kidney Int
; 103(4): 772-781, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738891
6.
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
Cardiovasc Diabetol
; 22(1): 66, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964557
7.
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Cardiovasc Diabetol
; 22(1): 126, 2023 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244998
8.
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
Diabetes Obes Metab
; 25(2): 435-443, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36199242
9.
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
Diabetes Obes Metab
; 25(10): 2989-2998, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37402696
10.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427295
11.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
; 65(7): 1085-1097, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445820
12.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Circulation
; 143(5): 470-478, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185476
13.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
N Engl J Med
; 381(9): 841-851, 2019 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185157
14.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 380(4): 347-357, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415602
15.
The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial.
Int J Obes (Lond)
; 46(5): 926-934, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022545
16.
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
Cardiovasc Diabetol
; 21(1): 172, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056351
17.
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
Cardiovasc Diabetol
; 21(1): 104, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35689214
18.
Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.
Diabetes Obes Metab
; 24(6): 969-982, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212443
19.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab
; 24(1): 94-105, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514682
20.
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Diabetologia
; 64(6): 1226-1234, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33611623